FDA Eases Compounding Rules for Newborn IV Nutrition

FDA issued guidance, effective immediately, that temporarily loosens compounding rules for starter parenteral nutrition (PN) drug products used to feed premature and critically ill newborns intravenously. The agency acted after children's hospitals warned of a looming supply gap: two outsourcing facilities that make standardized neonatal starter PN products are permanently shutting down, and there is no FDA-approved version of the product to fall back on. The Federal Register notice of availability for the guidance published 9 September; FDA's press announcement of the underlying action came five days earlier, on 4 September.

A product category with no approved version

Starter parenteral nutrition delivers nutrients intravenously to newborns who cannot yet feed by mouth or feeding tube — typically premature infants in the first days of life, before a clinician can formulate an individualized PN prescription. It is, in FDA's own framing, essential to the care of an especially vulnerable patient population. It is also a category where the agency has never approved a standardized product: the entire US supply runs through compounding, either by outsourcing facilities registered under section 503B of the Federal Food, Drug, and Cosmetic Act, or by State-licensed pharmacies and Federal facilities operating outside that registration.

That structural gap became urgent when two of the outsourcing facilities that supply standardized neonatal starter PN products announced they are permanently exiting the market. FDA says it learned of the resulting supply risk from children's hospitals directly — a signal that the shortage was already being felt operationally before the agency intervened.

What the guidance changes

The guidance describes FDA's temporary regulatory and enforcement priorities for compounding certain starter PN products for neonates. For outsourcing facilities, it grants temporary enforcement discretion around certain bulk drug substance restrictions and around stability-testing and expiration-date requirements that would otherwise apply. In exchange, it sets new floors: a facility must begin limited stability testing once its aggregate production of a given product is expected to exceed 5,000 units, and must begin container-closure integrity testing starting with the first batch it compounds under the policy.

• Enforcement discretion on select bulk-substance restrictions and stability/expiration-date requirements, for the duration of the policy.
• Stability testing trigger: required once aggregate production of a product is expected to exceed 5,000 units.
• Container-closure integrity testing required starting with each facility's first compounded batch.
• Labeling: compounded products must carry a default beyond-use date set out in Appendix B of the guidance.

A stopgap, not a fix

FDA frames the guidance explicitly as a temporary measure intended to bridge a supply gap while longer-term solutions are identified, not as a permanent change to how neonatal starter PN is regulated. The 180-day clock, running through 8 March 2027, gives outsourcing facilities and hospital pharmacies a defined window to scale up compounding capacity under the relaxed terms — and gives FDA a checkpoint to decide whether to extend, tighten, or let the policy lapse, depending on whether new supply has materialized by then. For compounders operating in this space, the guidance is now the operative rulebook; for hospital pharmacy and RA/QA teams managing neonatal formularies, the March 2027 sunset is the date to track.